We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aspen Pharma Agrees to Pay Almost $10 Million to Settle UK Anti-Competition Probe
Aspen Pharma Agrees to Pay Almost $10 Million to Settle UK Anti-Competition Probe
In a first for the UK’s Competition and Markets Authority (CMA), Aspen Pharma agreed to pay the National Health Service £8 million ($9.7 million) to settle anti-competition charges involving fludrocortisone acetate — an oral corticosteroid used to treat Addison’s disease and for other conditions.